# OnCo record pd-l1-cps-10-tnbc (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/pd-l1-cps-10-tnbc/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "pd-l1-cps-10-tnbc" ;
  schema:name "PD-L1 combined positive score 10 in triple-negative breast cancer"@en ;
  schema:alternateName "CPS 10 in TNBC"@en, "PD-L1 CPS of 10 or more"@en, "PD-L1-positive triple-negative breast cancer"@en, "22C3 CPS 10"@en, "SP142 IC 1 percent (IMpassion130)"@en ;
  schema:description "In metastatic triple-negative breast cancer the immunotherapy pembrolizumab is only given when a PD-L1 stain of the tumour scores 10 or more on the combined positive score, because that is the group in which the trial showed people lived longer. For early disease before surgery no PD-L1 test is needed: pembrolizumab helped regardless."@en ;
  schema:url <https://onco.cc/terms/pd-l1-cps-10-tnbc/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/PD-L1> ;
  schema:citation <https://doi.org/10.1016/s0140-6736(20)32531-9>, <https://doi.org/10.1056/nejmoa2202809>, <https://doi.org/10.1056/nejmoa1809615>, <https://doi.org/10.1056/nejmoa1910549>, <https://doi.org/10.1056/nejmoa2409932>, <https://www.nice.org.uk/guidance/ta801>, <https://www.nice.org.uk/guidance/ta851> ;
  onco:tag "breast", "tnbc" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:terms <https://onco.cc/terms/cps/>, <https://onco.cc/terms/tils/> ;
  onco:trials <https://onco.cc/trials/keynote-355/>, <https://onco.cc/trials/impassion130/>, <https://onco.cc/trials/keynote-522/> .